E3S Web Conf.
Volume 185, 20202020 International Conference on Energy, Environment and Bioengineering (ICEEB 2020)
|Number of page(s)||5|
|Section||Medical Biology and Medical Signal Processing|
|Published online||01 September 2020|
Exciting progress of cancer immunotherapy focusing on immune checkpoints
St. John’s Preparatory School, 72 Spring St, Danvers MA 01923, United States
* Corresponding author: email@example.com
Immune checkpoints blockade (ICB) has made revolutionary progress in cancer therapy recently. The development of blocking agents to checkpoints on coinhibitory pathway, which prevents inflammation-induced tissue damage but also induces the cancer immune evasion, and retrieves the productive immune responses against tumors. The striking clinical trial results of ICB, by targeting the cytotoxic T lymphocyte–associated protein 4 (CTLA-4), the programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1), has promoted the approval of multiple antibodies for several cancer types by the US Food and Drug Administration (FDA). In addition, the combination of multiple types of blockade even increased the efficacy of tumor regression. Following the previous success, other immune checkpoints have also been verified, such as lymphocyte-activated gene-3 (LAG-3) and Signal-regulatory Protein alpha (SIRPα). However, not all patients can get benefits from ICB and the mechanisms of these coinhibitory pathways are not quite clear. Therefore, understanding the mechanisms of ICB is a formidable challenge that could have far reaching guidelines for therapeutic strategies in cancer. This article summarizes the literature to date regarding ICB that may help more patients get benefit from immunotherapy.
© The Authors, published by EDP Sciences, 2020
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.